We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Third fiscal quarter 2022 total revenue of $100.2ย million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYXยฎ of $48.7 million in third fiscal quarter...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire NEW YORK, Dec. 16, 2022 NEW YORK, Dec. 16, 2022...
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciencesย (NYSE:ย MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...
BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November...
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have...
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (โMyovantโ) today announced the cancellation of its earnings conference call for the quarter ended September...
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovantย for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needsย in Womenโs Health and...
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 Sumitovant Biopharma to...
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciencesย (NYSE:ย MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions